Veligrotug PDUFA Date (Viridian Therapeutics)
FDA PDUFA decision date for Veligrotug is June 30, 2026. Developed by Viridian Therapeutics. Indication: Thyroid eye disease (TED). Current status: Approved.
Indication
Thyroid eye disease (TED)
Regulatory details
- Company: Viridian Therapeutics
- Therapeutic area: Rare Disease / Ophthalmology
- Application type: BLA
- Review type: Priority
- PDUFA date: 2026-06-30
- Outcome: Approved